Email Contact us - Question mark Help -

skip to main content
- Register - Forgotten Password?

New Technologies


Return to Current Test Trials.

The MLPA validation study by NoE of EuroGentest

Download the study as PDF hereDownload PDF Document

Validation of the MLPA method by EuroGentest

Introduction

Multiplex Ligation-dependent Probe Amplification (MLPA) is a method to establish the copy number of up to 40 different DNA sequences in an easy to perform reaction requiring only 20 ng of human DNA (Schouten et al., 2002). This technology is based on the identification of target sequences by hybridisation of pairs of MLPA probes that bind to adjacent sequences and are joined by a ligationreaction. The sequences are then simultaneously amplified with the use of only one primer pair, resulting in a mixture of amplification products, in which each PCR product of each MLPA probe has a unique length. These products can be electrophoresed on a capillary sequencer or on a gel, resulting in size separated chromatograms. The peak area or peak height of each amplification product reflects the relative copy number of that target sequence. The comparison of this pattern with a control sample enables the detection of deletions or duplications.

General overview of the MLPA principle
Fig. General overview of the MLPA principle

Aims

So far, no inter-laboratory collaborative programs have been undertaken to fully validate the MLPA method. Within the context of EuroGentest, 10-15 laboratories are willing to cooperate in this study. In addition, MRC-Holland distributes the "BRCA1 MLPA validation kit" to all the participants. DNA samples for positive and negative controls of BRCA1 are coming from NGRL Manchester and UMC Utrecht. They were extracted with the Gentra Autopure LS technology.

The purpose of this validation is to:

Work flow

In order to achieve these goals, the validation is subdivided in three different parts.

  1. First of all, the participating laboratories will perform MLPA on "negative" DNA samples (without copy number changes) using the "BRCA1 MLPA Validation kit" and their own protocols. These results will be collected to ascertain precision and performance parameters and to evaluate the overall inter-laboratory variability.
  2. Secondly, the laboratories will be asked to use their common Excel sheets and software programs to analyse a given set of MLPA files (DMD). In addition, three companies that develop MLPA analysis software, will perform the same evaluation, i.e. MRC-Holland (Coffalyser), SoftGenetics (GeneMarker) and JSI-Medical-Systems (Sequence Pilot). These results will be collected and compared to evaluate the IT tools regarding performance and internal quality control.
  3. In a final step, the participants will perform MLPA on a set of "positive" BRCA1 samples with known deletions or duplications, using the same "BRCA1 MLPA Validation kit" and their own protocols. After collection of the data, precision and performance parameters will be evaluated.

End result

The final outcome should be:

References


Last changed: 2008-11-04

Copyright EuroGentest Network of Excellence Project 2005 - EU Contract no.:FP6-512148 - Contact Us - FAQ - Privacy - Disclaimer - Accessibility - Standards - Advertising - Credits - RSS feeds - Valid XHTML 1.0 Transitional - Valid CSS!